VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Thursday, January 8, 2026
Stock Comparison
VINCI SA vs Gilead Sciences, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
VINCI SA
DG · Euronext Paris
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Gilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisComparison highlights
- Moat score gap: Gilead Sciences, Inc. leads (74 / 100 vs 57 / 100 for VINCI SA).
- Segment focus: VINCI SA has 7 segments (44.4% in VINCI Construction); Gilead Sciences, Inc. has 5 segments (68.5% in HIV).
- Primary market structure: Competitive vs Oligopoly. Pricing power: Weak vs Moderate.
- Moat breadth: VINCI SA has 7 moat types across 2 domains; Gilead Sciences, Inc. has 8 across 3.
Primary market context
VINCI SA
VINCI Construction
Construction and civil engineering contracting (buildings, infrastructure and specialty networks)
Global
Public-sector project owners and private developers/industrial clients
General contractor / civil engineering contractor
44.4%
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Side-by-side metrics
Moat coverage
Shared moat types
VINCI SA strengths
Gilead Sciences, Inc. strengths
Segment mix
VINCI SA segments
Full profile >VINCI Autoroutes
Monopoly
VINCI Airports
Oligopoly
Other concessions (incl. VINCI Highways and PPP assets)
Competitive
VINCI Energies
Competitive
Cobra IS
Competitive
VINCI Construction
Competitive
VINCI Immobilier
Competitive
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.